表紙:FOSMANOGEPIX:新薬の考察と市場予測 (2030年)
市場調査レポート
商品コード
974746

FOSMANOGEPIX:新薬の考察と市場予測 (2030年)

FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
FOSMANOGEPIX:新薬の考察と市場予測 (2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Fosmanogepixは、カンジダ菌血症やアスペルギルス症などの致死的な真菌感染症を対象とした新型の抗真菌剤で、現在は治験の第II相が終了したところです。米国FDA (食品医薬品局) より7種類の適応症についてファストトラックおよび希少疾病用医薬品の指定を受けており、4種類の適応症について認定感染症製品 (QIDP) の指定も受けています。

当レポートでは、現在治験中のカンジダ性菌血症の治療薬であるFOSMANOGEPIXの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 医薬品の概要

  • 製品の詳細情報
  • 作用機序
  • 用法・用量
  • 研究開発 (R&D) 活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国 (7MM) の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場参入企業

第6章 その他の新たな治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 FOSMANOGEPIX, Description
  • Table 2 FOSMANOGEPIX, Clinical Trial Description
  • Table 3 FOSMANOGEPIX, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of FOSMANOGEPIX
  • Figure 2 Patent Details, FOSMANOGEPIX
  • Figure 3 FOSMANOGEPIX, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 FOSMANOGEPIX, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 FOSMANOGEPIX, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 FOSMANOGEPIX, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0127

"FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Candidemia in 7 Major Markets. A detailed picture of the FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Fosmanogepix, is a novel broad-spectrum antifungal agent being evaluated in multiple clinical trials in patients with life-threatening fungal infections. Enrollment was recently completed in a Phase 2 trial evaluating the safety and efficacy of the intravenous and oral formulations of fosmanogepix for the treatment of patients with Candida infections. In that study, fosmanogepix demonstrated a high level of treatment success in the first 10 patients treated. Additional Phase 2 studies of fosmanogepix are ongoing in patients with Aspergillus and other mold infections, as well as infections caused by multi-drug-resistant Candida auris, a life-threatening fungal infection recently characterized as an "urgent" threat by the Centers for Disease Control.

Fosmanogepix has a novel mechanism of action, and its active moiety has shown broad-spectrum activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as C. auris and C. glabrata, as well as rare hard-to-treat molds including Fusarium, Scedosporium, and some fungi from the Mucorales order. Invasive fungal infections result in high mortality rates (30-80%), despite standard-of-care treatment. The frequency of fungi resistant to both the azole and echinocandin classes of drugs is increasing, and there is a significant unmet medical need for a new broad-spectrum antifungal agent.

Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP) for the treatment of four indications.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FOSMANOGEPIX.
  • The report contains forecasted sales for FOSMANOGEPIX till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Candidemia.
  • The report also features the SWOT analysis with analyst insights and key findings of FOSMANOGEPIX.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FOSMANOGEPIX Analytical Perspective by DelveInsight

  • In-depth FOSMANOGEPIX Market Assessment

This report provides a detailed market assessment of FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • FOSMANOGEPIX Clinical Assessment

The report provides the clinical trials information of FOSMANOGEPIX covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Candidemia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence FOSMANOGEPIX dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Candidemia are giving market competition to FOSMANOGEPIX and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of FOSMANOGEPIX.
  • Our in-depth analysis of the forecasted sales data of FOSMANOGEPIX from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FOSMANOGEPIX.

Key Questions:

  • Which company is developing FOSMANOGEPIX along with the phase of the clinical study?
  • What is the technology utilized in the development of FOSMANOGEPIX?
  • What is the product type, route of administration and mechanism of action of FOSMANOGEPIX?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FOSMANOGEPIX development?
  • What are the key designations that have been granted to FOSMANOGEPIX?
  • What is the forecasted market scenario of FOSMANOGEPIX?
  • What is the history of FOSMANOGEPIX and what is its future?
  • What is the forecasted sales of FOSMANOGEPIX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to FOSMANOGEPIX?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options